Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fatigue: definitions, mechanisms, and paradigms for study

M C Dalakas1, V Mock, M J Hawkins

  • 1The National Institute for Neurological Disorders and Stroke, Bethesda, MD, USA.

Seminars in Oncology
|March 3, 1998
PubMed
Summary

Interferon-alpha (IFN-alpha) therapy commonly causes fatigue, potentially linked to neuromuscular issues. Further research is needed to understand this side effect and develop effective treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations.

Lupus·2016
Same author

GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.

Journal of neuroimmunology·2015
Same author

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Clinical and experimental immunology·2014
Same author

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Clinical and experimental immunology·2014
Same author

Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis.

Journal of neuroimmunology·2013
Same author

Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.

European journal of neurology·2012

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Interferon-alpha (IFN-alpha) therapy frequently causes significant fatigue, often dose-limiting.
  • This fatigue is dose-related, worsens over time, and is linked to depression.
  • The exact cause of IFN-alpha-induced fatigue is unknown.

Purpose of the Study:

  • To explore the hypothesis that neuromuscular fatigue is a component of IFN-alpha-induced fatigue.
  • To investigate potential mechanisms underlying IFN-alpha-induced fatigue.
  • To inform the development of therapeutic interventions for IFN-alpha-induced fatigue.

Main Methods:

  • Investigate the potential role of neuromuscular fatigue, drawing parallels with postpolio syndrome.
  • Examine the induction of proinflammatory cytokines during IFN-alpha therapy as a potential mechanism.

Related Experiment Videos

  • Propose the use of established techniques for studying neuromuscular fatigue.

    • Main Results:

    • IFN-alpha therapy is associated with significant fatigue, a major dose-limiting side effect.
    • Fatigue is dose-dependent, progressive, and correlated with depression.
    • Proinflammatory cytokine induction suggests a possible neuromuscular pathology.

    Conclusions:

    • Neuromuscular fatigue may contribute to the fatigue experienced by patients on IFN-alpha therapy.
    • Understanding the etiology of IFN-alpha-induced fatigue is crucial for developing interventions.
    • Nonpharmacologic and pharmacologic interventions for fatigue are under investigation.